cell-free DNA

Clinicians say they are using blood-based tests for patients who can't be biopsied as a way to get test results sooner, but implementing tests smartly and appropriately remains a challenge.

While Cynvenio will still perform testing in its own lab right now, the firm's CEO said that interested labs could move the technology in house in the future if they desire.

Advanced cancer patients at the VA will now have access to the company's blood-based PlasmaSelect 64 test as well as the CancerSelect 125 tissue test.

Karius has made its assay available to early-access users and is collaborating on several clinical trials to demonstrate its ability to diagnose infection.

The company said that it has had interest so far in its focused Avenio kits as well as larger panels for surveillance and monitoring.

Though researchers highlighted their goal of using the method to move toward a test to detect early cancers, their current data speaks only to the method's performance in late-stage cancer patients.

New data points to strong predictive ability for a ddPCR-based test of AR copy number, while other companies are pursuing tests that target expression of AR splice variants.

Cirina will operate as a subsidiary of Grail and the combined entity will collaborate with Dennis Lo's lab at the Chinese University of Hong Kong. 

The company's test measures epigenetic alteration of two genes using Qiagen PCR methods, in order to detect signs of recurrence in colorectal cancer patients post-surgery.

The company's total revenues were $1.7 million, including $897,000 in commercial testing revenue. Its test volume was up 38 percent.

Pages

A University of California, Los Angeles-led team has found turning off the CCR5 gene could improve recovery after a stroke, according to Scientific American.

South Dakota lawmakers are to weigh a bill aimed at teaching the strengths and weaknesses of scientific concepts, the Associated Press and KEVN-Black Hills Fox report.

In Science this week: the synthetic genetic system hachimoji, and more.

Thermo Fisher Scientific says it will no longer sell machines in China's Xinjiang region, according to the Wall Street Journal.